UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 51

Sortiert nach

Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis

Canadian Medical Association journal, 2009-05, Vol.180 (11), p.E62

2009

Volltextzugriff (PDF)

Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort

Current oncology (Toronto), 2018-12, Vol.25 (6), p.384-392

2018

Volltextzugriff (PDF)

Application of Hereditary Renal Cell Carcinoma Risk Criteria to a Large Prospective Database

Clinical oncology (Royal College of Radiologists (Great Britain)), 2020-01, Vol.32 (1), p.e10-e15

2020

Volltextzugriff (PDF)

Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

The New England journal of medicine, 2023-02, Vol.388 (8), p.719-732

2023

Volltextzugriff (PDF)

Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma

Current oncology (Toronto), 2011-10, Vol.18 Suppl 2 (12), p.S11-19

2011

Volltextzugriff (PDF)

Continuity clinics in oncology training programs in Canada

Current oncology (Toronto), 2012-10, Vol.19 (5), p.e329-342

2012

Volltextzugriff (PDF)

Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience

Annals of oncology, 2016-10, Vol.27, p.vi285-vi285

2016

Volltextzugriff (PDF)

Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma

Current oncology (Toronto), 2011-10, Vol.18 (Suppl 2), p.S11-S19

2011

Volltextzugriff (PDF)

Genitourinary small cell carcinoma: a retrospective review of treatment and survival patterns at The Ottawa Hospital Regional Cancer Center

BJU international, 2006-04, Vol.97 (4), p.711-715

2006

Volltextzugriff (PDF)

Results of a phase II study of single-agent nab-paclitaxel in platinum-refractory second-line metastatic urothelial carcinoma (UC)

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.241-241

2011

Volltextzugriff (PDF)

Genitourinary (GU) small cell carcinoma (SCC): A retrospective review of treatment and survival patterns at the Ottawa Regional Cancer Center (ORCC)

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.4545-4545

2004

Volltextzugriff (PDF)

Genitourinary (GU) small cell carcinoma (SCC): A retrospective review of treatment and survival patterns at the Ottawa Regional Cancer Center (ORCC)

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.4545-4545

2004

Volltextzugriff (PDF)

LBA53Health-related quality of life (HRQL) in a randomized phase III trial of enzalutamide with standard first-line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Determining knowledge transfer gaps in the life cycle of evidence for chemotherapy in non-small cell lung cancer (NSCLC) through cumulative meta-analysis

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.6555-6555

2007

Volltextzugriff (PDF)

Randomized phase II trial of cisplatin/gemcitabine with or without LY293111, a multiple eicosonaid pathway modulator, in patients with chemotherapy naïve advanced non-small cell lung carcinoma

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.7024-7024

2006

Volltextzugriff (PDF)

Clinical evidence of efficacy of the temozolomide/gemcitabine combination against non-small cell (nsclc) and small cell (sclc) lung cancers

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.7338-7338

2005

Volltextzugriff (PDF)

A phase I safety and PK study of the novel vascular targeting agent (VTA), Exherin, in patients with refractory solid tumors stratified according to N-cadherin expression

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.3078-3078

2004

Volltextzugriff (PDF)

A phase I safety and PK study of the novel vascular targeting agent (VTA), Exherin, in patients with refractory solid tumors stratified according to N-cadherin expression

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.3078-3078

2004

Volltextzugriff (PDF)

A generative co-design framework for healthcare innovation: development and application of an end-user engagement framework

Research involvement and engagement, 2021-03, Vol.7 (1), p.12-12, Article 12

2021

Volltextzugriff (PDF)

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma

Journal of clinical oncology, 2017-12, Vol.35 (35), p.3916-3923

2017

Volltextzugriff (PDF)

Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury

Nature genetics, 1996-05, Vol.13 (1), p.43-47

1996

Volltextzugriff (PDF)

Mice lacking cytosolic copper/zinc superoxide dismutase display a distinctive motor axonopathy

Neurology, 1999-10, Vol.53 (6), p.1239

1999

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(49)
Bücher
(1)
Reviews
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(26)
Life Sciences & Biomedicine
(25)
Humans
(16)
Male
(10)
Oncology
(9)
Female
(7)
Adult
(6)
Aged
(6)
Middle Aged
(6)
Urology & Nephrology
(6)
Renal Cell Carcinoma
(5)
Antineoplastic Agents - Therapeutic Use
(4)
Biological And Medical Sciences
(4)
Canada
(4)
Chemotherapy
(4)
Nephrectomy
(4)
Survival Analysis
(4)
Aged, 80 And Over
(3)
Animals
(3)
Carcinoma, Renal Cell - Drug Therapy
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis

Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort

Application of Hereditary Renal Cell Carcinoma Risk Criteria to a Large Prospective Database

Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma

Continuity clinics in oncology training programs in Canada

Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience

Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma

Genitourinary small cell carcinoma: a retrospective review of treatment and survival patterns at The Ottawa Hospital Regional Cancer Center

Results of a phase II study of single-agent nab-paclitaxel in platinum-refractory second-line metastatic urothelial carcinoma (UC)

Genitourinary (GU) small cell carcinoma (SCC): A retrospective review of treatment and survival patterns at the Ottawa Regional Cancer Center (ORCC)

Genitourinary (GU) small cell carcinoma (SCC): A retrospective review of treatment and survival patterns at the Ottawa Regional Cancer Center (ORCC)

LBA53Health-related quality of life (HRQL) in a randomized phase III trial of enzalutamide with standard first-line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial

Determining knowledge transfer gaps in the life cycle of evidence for chemotherapy in non-small cell lung cancer (NSCLC) through cumulative meta-analysis

Randomized phase II trial of cisplatin/gemcitabine with or without LY293111, a multiple eicosonaid pathway modulator, in patients with chemotherapy naïve advanced non-small cell lung carcinoma

Clinical evidence of efficacy of the temozolomide/gemcitabine combination against non-small cell (nsclc) and small cell (sclc) lung cancers

A phase I safety and PK study of the novel vascular targeting agent (VTA), Exherin, in patients with refractory solid tumors stratified according to N-cadherin expression

A phase I safety and PK study of the novel vascular targeting agent (VTA), Exherin, in patients with refractory solid tumors stratified according to N-cadherin expression

A generative co-design framework for healthcare innovation: development and application of an end-user engagement framework

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma

Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial

Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury

Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP

Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy

Mice lacking cytosolic copper/zinc superoxide dismutase display a distinctive motor axonopathy

Suchergebnisse filtern